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Aims   
To examine the incidence of type 2 diabetes in people with newly diagnosed 
prediabetes and the factors that protect against this progression. 
 
Methods 
The study population was 14,043 adults with pre-diabetes enrolled in a primary health 
organization in the upper North Island of New Zealand. Glycated hemoglobin (HbA1c) 
and body mass index (BMI) were linked to government health, census and social 
datasets in the Statistics New Zealand Integrated Data Infrastructure. Adults with a first 
diagnosis of pre-diabetes between 2009 and 2017 (HbA1c in range 5.9-6.6% [41-49 
mmol/mol]) were followed-up for type 2 diabetes incidence. Cox regression was used to 
examine protective factors and adjust for potential confounding.  
 
Results 
Cumulative diabetes incidence was 5.0% after three years. Progression was greater in 
younger adults, men, people with higher HbA1c, greater BMI and a more recent 
diagnosis. Progression was lower in people treated with metformin, and Indigenous 
language speakers. Higher progression rates for Māori (Indigenous population) and 
Pacific peoples (migrants to New Zealand) were related to higher baseline HbA1c.  
 
Conclusions 
This is the first study to identify Indigenous language as a protective factor against 
diabetes, and results confirm obesity as a key target for population prevention. People 











Pre-diabetes (intermediate hyperglycemia) is a predictor of progression to type 2 
diabetes mellitus [1-5] and an independent risk factor for cardiovascular disease [6]. 
Globally, rates of obesity, pre-diabetes and diabetes have increased and it is projected 
that >470 million people will have pre-diabetes by 2030 [7]. A quarter of adults in New 
Zealand had pre-diabetes in 2008/09 and 7% had diabetes (using the 2010 American 
Diabetes Association criteria) [8].  
 
Rates of progression from pre-diabetes to diabetes internationally range from around 2-
18% per year but previous studies have generally measured progression by a glucose 
based test (fasting glucose or oral glucose tolerance test) and many of these studies 
are under trial conditions [1-5]. HbA1c has become an acceptable and common first-line 
test for diagnosis of pre-diabetes and diabetes internationally [9] yet progression of pre-
diabetes defined by HbA1c has rarely been studied. Improved understanding of how 
new HbA1c criteria impact on diabetes risk is needed. Accurate pre-diabetes 
progression rates are important for planning and monitoring interventions to prevent 
diabetes in people with pre-diabetes.  
 
Evidence is building for the benefits of intensive diet and lifestyle and other novel 
interventions for pre-diabetes. Trial evidence suggests that structured lifestyle changes 
(physical activity and diet), BMI reduction and treatment with metformin are important 
for protecting against pre-diabetes progression [4, 10]. An understanding of risk by age, 
sex, socioeconomic position (SEP) and ethnicity is important to help target programs to 
the right population groups and to monitor their success over time. Furthermore there 
are concerns about using pre-diabetes as a singular category if rates of pre-diabetes 
progression are low, or the risk of diabetes is no different from people with a 
combination of other risk factors [7]. For these reasons it is important to determine pre-
diabetes progression, and do so using HbA1c testing.  
 
Differences in diabetes incidence by ethnicity are common internationally [11-14], 
however more information is required to identify the key policy levers and interventions 
to address ethnic disparities. For example, the highest rates of diabetes in adult New 
Zealanders are among Indian and Pacific peoples (24%) [15, 16]. Māori – the 
Indigenous population in New Zealand – also experience a disproportionate share of 
obesity and diabetes (16%) compared to European peoples (6%) [15]. Little has been 
done to implement interventions that effectively curb the growing tide of obesity 
worldwide, particularly for indigenous and minority populations. Such inaction in the face 
of need has been recognized as institutionalized racism [17].  
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In New Zealand, regular HbA1c testing has become more widespread since 2002 as 
part of a broader cardiovascular risk assessment (CVRA) – making a cohort study of 
progression from pre-diabetes to diabetes using routine data possible. CVRAs are 
recommended at least once every five years, and more frequently for people at the 
higher risk. The eligible age for CVRA is 55-74 years old for European/Other women; 
45-74 years old for European/Other men and Māori, Pacific or Indian Subcontinent 
women; and 35-74 years old for Māori, Pacific or Indian men. In June 2016, CVRA 
coverage was 90% nationally and 92% within the studied primary care population [18]. 
Individuals who are 75 years or older are recommended ongoing annual cardiovascular 
review. These settings allow a study HbA1c defined pre-diabetes and its progression.  
 
The aim of this study was to first, examine the incidence of diabetes in an ethnically-
diverse primary care population with newly diagnosed pre-diabetes; and second, to 
quantify the factors that protect against progression to diabetes, with an emphasis on 
non-clinical as well as clinical factors. The question posed in this paper was developed 
in response to issues raised as part of an Indigenous community co-design project that 
used the He Pikinga Waiora Implementation Framework [19]. The framework is a 
participatory approach to developing and implementing interventions that places Māori 
knowledge and self-determination at the center and then integrates systems thinking to 





2.1 Primary care cohort  
A primary health organization in New Zealand with practices in Auckland (primarily), 
Waikato and Whanganui and an enrolled population of 130,000 was selected as the 
source population, given its diversity with 16% who identified as Māori, 14% Pacific, and 
35% Asian (using Statistics New Zealand classifications). Asian and Pacific peoples had 
a greater representation than in the overall New Zealand population (15% Māori, 7% 
Pacific, 12% Asian, 2013 census). Eligible individuals were aged 25 years and older, 
with a first-time reported diagnosis of pre-diabetes (glycated hemoglobin [HbA1c] in 
range 5.9-6.6% [41-49 mmol/mol]), and at least one subsequent HbA1c test result. In a 
cohort study design, individuals were followed up from the time they were first 
diagnosed with pre-diabetes (baseline) to determine whether they got type 2 diabetes 
(HbA1c 6.7%+ / ≥50 mmol/mol). We used HbA1c for diabetes diagnosis because it was 
the recommended first-line test for diagnosis of type 2 diabetes during the study period 
and was likely to be available for everyone who developed diabetes during the study 
period HbA1c criteria differed from those of the American Diabetes Association who 
recommend a lower but overlapping range (HbA1c between 5.7-6.4% [39-47mmol/mol]) 
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[9]. The WHO does not offer any recommendation on HbA1c criteria for pre-diabetes, 
but defines diabetes similarly to the ADA with a HbA1c of 6.5% (48mmol/mol) or more 
[20]. 
 
Individuals were excluded if they had a pre-existing diagnosis of diabetes recorded in 
primary care HbA1c test records or in the Ministry of Health Virtual Diabetes Register 
(that predicts who has diabetes based on algorithms run across hospital, 
pharmaceutical and outpatient records) [21, 22]. Women were excluded if they had a 
hospital admission with a diagnosis of hyperglycemia or diabetes in pregnancy, 
because pregnancy related hyperglycemia was not the focus of this study. 
 
Ethical approval was awarded by the Otago Human Ethics Committee (HD16/002, 20th 
September 2016). Patients enrolled in the Primary health organisation sign to agree to 
the use of their health information for research as approved by an ethics committee.  
 
2.2 Data  
There were three sources of variables that were linked: variables recorded in primary 
care records, health-related variables recorded in national datasets held by the Ministry 
of Health, and socio-demographic variables held in other national datasets in the 
Statistics New Zealand Integrated Data Infrastructure (IDI). The IDI is a government-led 
research database of administrative, survey and non-government data.  
Linkage was achieved by deterministically linking the primary care data to health data in 
the IDI [23] using the national health index (NHI) number (99.7% of records were 
successfully linked). The health data in the IDI were then probabilistically linked to the 
IDI spine by Statistics New Zealand in the September 2017 refresh, using common 
variables such as name, age and sex (85% of health records were linked). The IDI 
spine is a central list of individual records of people who have ever been a resident, and 
this list is comprised using tax records, visa information and birth records [24]. The 2013 
census data was also probabilistically linked to the IDI spine. Supplementary Figure S1 
outlines a flow diagram outlining linkage between datasets. These linked datasets were 
used to create the following variables.  
 
HbA1c test results and BMI measures were generated from primary care records. BMI 
records were selected if recorded in the five years before baseline or 30 days after, and 
were categorized into standardized groupings. Extreme BMI measures were excluded 
(eg <10kg/m2 and >1m, or >100kg/m2 and <1m).  
 
Ministry of health datasets were used to identify antidepressant use (five years prior to 
baseline), most recent primary care consultation at baseline, existing diabetes and other 
chronic conditions (within the five years prior to baseline), metformin treatment during 
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follow-up (pharmaceutical dataset), bariatric surgery, and hospital admission with 
diabetes/hyperglycemia in pregnancy. 
 
IDI summary tables draw on multiple datasets and were used to identify basic 
demographic information; age (ten year groups), sex, ethnicity (self-identified ethnicity 
from the 2013 census if available otherwise it was taken from health or other datasets; 
individuals were allowed to identify with one or more groups termed here total ethnicity), 
New Zealand deprivation index (small area index of socioeconomic position [25]) and 
mobility (number of small residential areas someone has lived in the five years prior to 
baseline).  
 
Personal income quintiles were extracted from Inland Revenue Department (tax) 
summary tables (with data up to the third quarter of 2015, excludes self-employed and 
investment income). The 2013 census was used for indicators of highest qualification, 
equivalised household income (quintiles based on national income pattern), household 
crowding (Canadian National Occupancy Standard), labor force status, home 
ownership, smoking status and te reo speaking (Indigenous Māori language). The te reo 
association was tested across all ethnic groups and an interaction term was used to test 
if this association varied by Māori/non-Māori. Variables of interest were informed by 




The pre-diabetes study population and key variables were described including the 
pattern of missing data. Estimates of diabetes prevalence at 3 years post-diagnosis 
were produced using Kaplan Meier survival analysis for each ten year age group and by 
sex, ethnicity, baseline HbA1c, education, deprivation, household income and time 
period. These analyses were done on the full available dataset. 
 
Proportional hazards (Cox) regression models were used to estimate the association 
between variables of interest and pre-diabetes progression. Analyses were run on the 
‘non-missing dataset’ that had no missing data on education, personal income or 
deprivation. These SEP variables were the only variables in the full model that had 
missing data. A univariate analysis model was run for each of the variables of interest. 
Second, the same models were run with adjustment for age and sex. Third, additional 
adjustment was made for prioritized ethnicity (mutually exclusive groups prioritized by 
Māori, Pacific, Asian then non-Māori/Pacific/Asian termed European/Other), education, 
personal income, neighborhood deprivation, and baseline HbA1c. For the association 
between metformin and pre-diabetes progression, further models were run with 
additional adjustment for BMI (Table S5). Analyses of census risk factors were limited to 
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the group of people with pre-diabetes that was diagnosed after the census (5th of March 
2013) to avoid reverse causality (with the one exception of highest qualification which 
was not expected to change during the study period). 
 
A sensitivity test was done to assess the effect of excluding records with missing SEP 
data. A model with adjustment for age, sex, ethnicity (prioritized to create mutually 
exclusive groups) and HbA1c was run for each variable of interest on the full set of 
available data. The same model was run on the restricted non-missing dataset used in 
the above regression analyses. Model results were compared to assess the possible 
extent of selection bias. All analysis was done using SAS.[26] 
 
3. Results  
14,043 individuals with pre-diabetes met the inclusion criteria, from a total of 65,802 
individuals with at least one HbA1c record. The study group was followed up for a total 
of 432,645 person months to calculate diabetes incidence. Regression analyses were 
carried out on the two-thirds of individuals (n=9,222) in the ‘non-missing dataset’. 
 
3.1 Pre-diabetes population 
The study population was a relatively deprived subset of the New Zealand population 
with a high proportion of Asian (41%) and Pacific peoples (16%), and 13% who 
identified as Māori (Table 1). One quarter of individuals had missing data for each of 
education and personal income, and three-quarters for BMI.  
 
3.2 Diabetes incidence 
The cumulative incidence of diabetes was 4.95% (95%CI 4.53-5.42) at three years. This 
figure was 1.04% (0.88-1.23) at one year, 2.99% (2.69-3.32) at two years, 7.65% (7.00-
8.35) at four years and 9.45% (8.52-10.48) at five years. Three-year cumulative 
diabetes incidence demonstrated different progression rates by age, ethnicity, HbA1c, 
BMI, equivalised household income and time period (Table 2). Progression was 5.8% 
for men and in women it was 4.2%. Diabetes incidence for Māori was 7.5%, Pacific 
7.6%, Asian 6.0% and European 4.9%.  
 
3.3 Protective factors: multivariable analyses 
Cox regression model estimates adjusted for age, sex, ethnicity, SEP and HbA1c are 
presented in Table 3 with separate models for each variable of interest. Women 
experienced one-third lower (RR 0.67 CI:0.54-0.82) progression rates than men. By 
age, the highest progression rates were in 35-44 year olds, who had nearly three times 
higher diabetes incidence than 65+ year olds, who had the lowest progression rates. 
After adjusting for HbA1c status, rates of progression were similar by ethnicity, however 
before adjusting for HbA1c and SEP, Māori had 1.49 (1.07-2.07) and Pacific had 1.46 
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(1.09-1.97) times greater progression than European/Other whereas progression in 
Asian people was more similar to European/Other (RR 1.05 CI:0.81-1.36).  
 
There was a strong protective association between speaking te reo (Indigenous 
language) and progression to diabetes (RR 0.31 CI:0.12-0.81). Sensitivity tests 
suggested that this result was only partially affected by missing data bias. We tested 
whether the association with te reo was any more or less protective for Māori than non-
Māori, but there was no evidence (p=0.975) of any interaction. Power for this test was 
limited because the number of non-Māori who were fluent in te reo was low.  
 
Glycated hemoglobin at baseline was strongly (p<0.001) and independently associated 
with progression to diabetes with a clear dose-response relationship (RR 55.6 CI:33.3-
90.9 for HbA1c 49 vs 41 mmol/mol). BMI was independently associated (p=0.033) with 
progression to diabetes with a dose-response relationship (RR 3.68 CI:1.39-9.72 
comparing 40+ vs <25 kg/m2). There was weak (p=0.067) evidence that smoking (RR 
1.52 CI:1.01-2.30) and ex-smoking (RR 1.42 CI:0.98-2.07) were associated with greater 
diabetes incidence compared to never smoking. The impact of missing data suggests 
the risk of ex-smoking may be less than is reported here (Appendix 1: sensitivity 
analysis).  
 
There was no evidence that chronic health conditions at baseline, home ownership, 
household crowding, rurality, mobility, primary care access and personal income were 
associated with pre-diabetes progression. Although tertiary education and full-time and 
part-time work appeared to be protective, there was no statistical evidence of an 
association with these factors. 
 
Metformin treatment was associated with an 88% decreased progression to diabetes 
(RR 0.12 CI:0.02-0.85) (Table S5). In sensitivity analyses, missing data on SEP and 
BMI shifted results but each in opposite directions.  
 
4. Discussion 
After three years 5% of people with pre-diabetes had developed diabetes, but this 
varied significantly by age, sex, HbA1c, ethnicity, Indigenous language, BMI, smoking 
(weaker evidence) and metformin treatment.  
 
Progression rates in the current study were generally lower than that found by earlier 
studies [1-5] (2.5-18% at one year) particularly in trials (5.8-18.3% at one year). This 
may be partially due to the higher coverage of HbA1c testing in this contemporary 
primary care cohort, which may have resulted in a healthier study population however 
this does not seem to be the full picture. A 2006 trial in India had a slightly higher 
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average baseline HbA1c than this study (44.3 vs 42.9 mmol/mol) and high progression 
rates (18% per year in control group) [3] whereas a 2017 observational study in Japan 
had similar progression rates to this study (2.5% per year) and a much lower baseline 
HbA1c (38 mmol/mol) [5]. Pre-diabetes was defined in our study with an HbA1c test 
with criteria of 5.9-6.6% [41-49 mmol/mol] when most previous studies have defined 
pre-diabetes using a glucose based test (or both) [1-5]. It is likely that differences in 
definitions influence rates of progression but further studies using HbA1c in 
contemporary primary care population would help to understand the extent of this.  
 
Three year, progression rates varied from 1% at a baseline HbA1c of 5.9% 
(41mmol/mol, after 3 years) to 40% with a HbA1c of 6.6% (49 mmol/mol) (considered 
diabetes using ADA criteria). This reflects the biological continuum of glycemic status 
and the challenge of selecting criteria for diagnosis of diabetes. At the lower end of the 
spectrum there is a concern that pre-diabetes might be a target for over medicalization 
and treatment (especially with an absence of other risk factors), when the risks of 
diabetes and cardiovascular complications are likely to be low. The pre-diabetes 
spectrum of HbA1c is a way of targeting diabetes prevention activities and is important 
for the evaluation of these interventions.  
 
Progression was greater in men and in the 35-44 year old age group, independent of 
baseline HbA1c. Progression rates appeared to be greater in sex-ethnicity groups that 
were younger than the CVRA HbA1c screening age cut-offs. This means that people 
tested at younger ages are likely to be at higher risk, compared to age groups where 
more people (90+%) are screened, and more people already have diabetes. 
Furthermore, younger people with prediabetes are likely to be on a faster trajectory to 
diabetes than older people who get prediabetes. 
 
Māori and Pacific peoples had greater progression rates than New Zealand European 
peoples, but this result was completely attenuated by adjusting for HbA1c. This is 
because Māori and Pacific peoples had higher baseline HbA1c levels than other ethnic 
groups. SEP factors such as tertiary education, employment and household crowding 
were protective but did not remain statistically significant after adjusting for ethnicity and 
HbA1c. Study results appear to reflect the different HbA1c distribution 
(normoglycaemia, pre-diabetes and diabetes) by ethnicity and SEP. Higher HbA1c at 
diagnosis may also be related to the slightly lower HbA1c testing rates (or less frequent 
tests) in Māori (88%, 2018) and Pacific (90%) than European (92%) and greater barriers 
to accessing primary health care [27].  
 
A cultural protective factor was the evidence of an association between speaking te reo 
(Indigenous language, with 87% of te reo speakers being Māori) and 19 to 88% lower 
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progression to diabetes, independent of age, sex, income, education, deprivation, 
ethnicity and HbA1c. This finding suggests that language and cultural identity are 
positive for health, particularly in Indigenous communities. This is the first known study 
to examine a relationship between diabetes and Indigenous language, and results are 
consistent with the protective association found between traditional language and 
suicide [28].  
 
BMI was strongly independently associated with progression, as has been 
demonstrated elsewhere [29]. Similarly, smoking was found to increase progression of 
pre-diabetes to diabetes (weak evidence), consistent with several studies [30, 31] but 
not all [32]. BMI and smoking are both important targets for population prevention of 
diabetes. Metformin treatment resulted in a large 92% reduction in progression. The 
direction of this finding is consistent with randomized trial evidence [33] however the 
magnitude was greater than expected. The 3.9% of people selected for metformin 
treatment may have been less likely to get diabetes for other reasons; they were being 
treated for polycystic ovary syndrome or they were also receiving other lifestyle 
interventions. Justification for metformin treatment at lower levels of HbA1c requires 
stronger evidence for reduced cardiovascular disease and other complications.  
  
4.1 Strengths and weaknesses 
This study links nearly a decade of contemporary primary care data (2009-2017) from a 
diverse primary care population to a national research data base of integrated 
administrative and survey data (IDI) to create a pre-diabetes cohort study. Our results 
are relevant to countries where HbA1c screening is increasingly being used.  
 
We were able to adjust and examine for many factors, however unmeasured factors 
may have confounded some of our results, such as diet or physical activity, sleep and 
stress, hypertension and hypercholesterolemia. These factors however are unlikely to 
have caused any confounding for the more distal social factors that were examined. 
Furthermore, the impact of renal function, hepatic function and inflammatory status on 
progression was not investigated because this data is likely to be incomplete; and nor 
was the impact of medications such as ACE-inhibitors, Angiotensin II receptor blockers, 
diuretics, corticosteroids, statins or estroprogestins that may affect glucose 
homeostasis. 
 
This study focuses on the engaged primary care population. We excluded people who 
were not enrolled in primary care or who had only one recorded HbA1c test. If 
unenrolled or infrequently tested individuals have higher rates of prediabetes 
progression, study progression may be underestimated. Also it is possible that despite 
frequent use of HbA1c as a first-line test for type 2 diabetes, some people may have 
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been diagnosed via oral glucose tolerance tests and not have been HbA1c tested (at 
least until later follow-up). This may have slightly underestimated prediabetes 
progression.  
 
This study had complete data on key variables such as age, sex, ethnicity and HbA1c. 
However, there was missing data for BMI, personal income and education. This is for 
two possible reasons; one, there were no available records (BMI, census records); or 
two, an individual’s health record could not be probabilistically linked to the IDI spine, or 
the spine record could not be probabilistically linked to the census record. However, 
98% of non-Māori and 97% of Māori health records were linked to the spine (linkage 
rates are lower for older people and Asian and Pacific peoples), and 94% of census 
data were linked to the IDI spine. The impact of missing SEP data was examined by 
sensitivity analysis but did not appear to have a major impact on key findings 




Public health solutions are required to prevent the rising tide of diabetes and address its 
structural drivers, including the obesogenic environment and tobacco control policy. 
More is needed at multiple levels; from limiting access to profit making and health 
negative industries to indigenous and socioeconomically deprived environments to 
increasing access to health protective factors at Indigenous community, family and 
individual levels. Ethnic inequities in diabetes progression represent both a range of 
unaddressed systems and structural problems and unmet need for healthcare. Under 
the United Nations Declaration on the Rights of Indigenous Peoples, member states are 
obliged to take the necessary steps to ensure indigenous people’s full rights to health 
are met. Te reo findings here suggest the importance of cultural connectedness for 
health and are encouraging for more advanced research in this area to be developed.  
 
Lifestyle interventions can reduce pre-diabetes progression and prioritizing more 
intensive intervention by age, sex, ethnicity, HbA1c, and BMI has the potential to 
improve cost-effectiveness [34]. The manner in which lifestyle interventions are 
developed appears to be as important as the content included [19]. Further research on 
the effectiveness and cost-effectiveness of pre-diabetes interventions by level of HbA1c 
would help determine how future lifestyle interventions should be targeted. More 
research is needed on the health impact at lower HbA1c levels given the low rates of 





This contemporary study of a pre-diabetes cohort from a well screened primary care 
population demonstrated lower rates of diabetes progression than expected. Indigenous 
language, lower BMI and never smoking were protective against pre-diabetes 
progression and are targets for prevention policies. Groups at high risk of diabetes 
identified by age, sex, ethnicity, HbA1c and BMI could be considered for prioritization of 
pre-diabetes interventions.  
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Table 1: A description of the study primary care population of adults 25+ years old with pre-diabetes, 2009-
2017 
  Men Women 
Population n 6624 7419 
Developed diabetes n 354 (5.3%) 276 (3.7%) 
Person-months follow-up Sum 204,174 228,471 
Mean 30.8 30.8 




Māori  789 (12%) 990 (13%) 
Pacific 1107 (17%) 1149 (15%) 
Asian 2649 (40%) 3150 (42%) 
European 2301 (35%) 2535 (34%) 
Age (%)  25-34 years 411 (6%) 525 (7%) 
35-44 years 1188 (18%) 1011 (14%) 
45-54 years 1743 (26%) 1794 (24%) 
55-64 years 1683 (25%) 2043 (28%) 
65+ years 1599 (24%) 2049 (28%) 
BMI at baseline (%) <25 378 (6%) 513 (7%) 
25-30 627 (9%) 489 (7%) 
30-35 408 (6%) 390 (5%) 
35-40 168 (3%) 237 (3%) 
40+ 126 (2%) 207 (3%) 
Missing 4920 (74%) 5586 (75%) 
Glycated hemoglobin at 
baseline, HbA1c 
(mmol/mol) 
41 2094 (32%) 2304 (31%) 
42 1551 (23%) 1740 (23%) 
43 1074 (16%) 1149 (15%) 
44 708 (11%) 825 (11%) 
45 435 (6.6%) 516 (7%) 
46 309 (4.7%) 351 (4.7%) 
47 192 (2.9%) 255 (3.4%) 
48 153 (2.3%) 150 (2%) 
49 108 (1.6%) 126 (1.7%) 
Personal income quintile 
(tax records, 5 years) 
Lowest Income 1059 (16%) 1278 (17%) 
Second Income 1113 (17%) 1338 (18%) 
Middle Income 852 (13%) 1521 (21%) 
Fourth Income 1122 (17%) 1251 (17%) 
Highest Income 1533 (23%) 864 (12%) 
Missing 948 (14%) 1161 (16%) 
NZ Deprivation Index 
(2013) quintile in area of 
residence at baseline 
Least deprived 732 (11%) 792 (11%) 
Second deprived 1104 (17%) 1104 (15%) 
Middle deprived 1251 (19%) 1425 (19%) 
Fourth deprived 1689 (25%) 1929 (26%) 
Most deprived 1719 (26%) 2040 (27%) 
 Missing 129 (2%) 129 (2%) 
Education (census) No qualification 1170 (18%) 1443 (19%) 
 School qualification 2589 (39%) 2895 (39%) 
 Tertiary qualification 1035 (16%) 1158 (16%) 
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 Missing 1833 (28%) 1926 (26%) 
Time Period 2009-2013 3717 (56%) 4116 (55%) 
 2014-2017 2907 (44%) 3306 (45%) 
Metformin Treated  228 (3.4%) 318 (4.3%) 
Not treated 6396 (96.6%) 7098 (95.7%) 
Notes: All numbers are random rounded to base three to meet Statistics New Zealand confidentiality requirements. 
Percentages are a proportion of the total numbers of men and women in the study. *These individuals had complete 






Table 2: Kaplan Meyer type 2 diabetes incidence estimates (percentage of people with pre-diabetes who had 
HbA1c ≥50 mmol/mol at 3 years) with 95% confidence intervals, in 25+ year olds, 2009-2017 
  Incidence diabetes at three years, percent (95% CI) 
Variable Category Men Women 
Total All 5.84 (5.18-6.58) 4.15 (3.63-4.75) 
Age  
 
25-34 years 7.32 (4.50-11.8) 3.91 (2.07-7.32) 
35-44 years 8.03 (6.22-10.3) 5.04 (3.56-7.12) 
45-54 years 6.68 (5.39-8.27) 5.92 (4.71-7.43) 
55-64 years 4.98 (3.88-6.39) 3.66 (2.80-4.77) 
65+ years 4.18 (3.16-5.54) 2.84 (2.10-3.85) 
Ethnicity (multiple 
response) 
Māori  7.52 (5.46-10.3) 4.96 (3.52-6.98) 
Pacific  7.55 (5.87-9.69) 5.47 (4.12-7.24) 
Asian  5.95 (4.91-7.19) 4.26 (3.44-5.27) 




41 1.09 (0.63-1.89) 0.71 (0.38-1.31) 
42 1.72 (1.09-2.72) 1.10 (0.62-1.92) 
43 3.12 (2.03-4.78) 2.54 (1.61-4.00) 
44 6.28 (4.45-8.84) 2.85 (1.73-4.68) 
45 8.58 (6.00-12.2) 5.70 (3.71-8.69) 
46 20.3 (15.4-26.5) 10.8 (7.53-15.4) 
47 23.1 (16.8-31.2) 19.0 (14.2-25.1) 
48 40.5 (31.7-50.6) 33.1 (24.9-43.1) 
49 43.6 (32.8-56.3) 37.7 (28.0-49.3) 
BMI (kg/m
2
) <25 2.98 (1.43-6.17) 1.09 (0.46-2.61) 
 25-29 4.82 (3.04-7.59) 4.34 (2.09-8.89) 
 30-34 7.38 (3.78-14.2) 3.57 (1.68-7.52) 
 35-39 20.2 (11.0-35.3) 7.32 (3.97-13.3) 
 40+ 15.1 (8.06-27.3) 17.8 (10.7-28.8) 




Lowest 5.35 (3.69-7.74) 4.87 (3.23-7.30) 
Second 5.17 (3.17-8.39) 4.26 (2.77-6.53) 
Middle 6.04 (3.64-9.93) 3.05 (1.40-6.59) 
Fourth 5.10 (3.09-8.35) 2.76 (1.47-5.18) 
Highest 3.22 (1.48-6.95) 3.26 (1.70-6.24) 
 Missing 6.11 (5.30-7.04) 4.29 (3.64-5.05) 
NZ Deprivation 
Index (2013) 
quintile at baseline 
Lowest 4.48 (2.89-6.92) 3.53 (2.25-5.52) 
Second 4.37 (3.09-6.16) 3.50 (2.31-5.28) 
Middle 5.19 (3.85-6.97) 3.88 (2.82-5.34) 
Fourth 6.67 (5.37-8.27) 4.00 (3.07-5.20) 
Highest 6.72 (5.41-8.34) 4.53 (3.57-5.75) 
Education (census) No qualification 4.93 (3.62-6.69) 4.55 (3.46-5.98) 
 School Qualification 5.98 (4.97-7.19) 3.82 (3.05-4.77) 
 Tertiary qualification 4.36 (3.05-6.22) 3.24 (2.15-4.85) 
 Missing 5.96 (5.14-6.91) 4.09 (3.43-4.86) 
Time period (year) 2009-2013 5.60 (4.87-6.44) 3.87 (3.29-4.54) 
 2014-2017 7.09 (5.31-9.42) 6.09 (3.66-10.1) 
Note: No age standardization. 
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Table 3: Proportional hazards/Cox multivariate regression models comparing the relative incidence of type 2 diabetes (rate ratio) for each variable of 
interest, 25+ year olds.  







 adjusted models 
  Rate ratio p Rate ratio p Rate ratio p 
Sex Females vs Males 0.64 (0.53-0.79) <0.001 0.66 (0.54-0.81) <0.001 0.67 (0.54-0.82) <0.001 
Age group 35-44 vs 25-34 years old 1.72 (1.03-2.91) <0.001 1.66 (0.98-2.79) <0.001 1.55 (0.92-2.63) <0.001 

















 Māori vs European/Other  1.71 (1.24-2.37) <0.001 1.49 (1.07-2.07) 0.012 0.95 (0.68-1.34) 0.321 
Pacific vs European/Other 1.78 (1.34-2.38)  1.46 (1.09-1.97)  0.85 (0.63-1.17) 
 Asian vs European/Other 1.25 (0.97-1.59)  1.05 (0.81-1.36)  0.76 (0.58-1.00) 
 Total ethnicity
||
 Māori  vs non-Māori 1.40 (1.05-1.86) 0.023 1.34 (1.00-1.79) 0.048 1.09 (0.81-1.48) 0.559 
 Pacific vs non-Pacific 1.48 (1.16-1.90) 0.002 1.33 (1.04-1.71) 0.025 0.96 (0.74-1.25) 0.766 
 Asian vs non-Asian 0.97 (0.79-1.19) 0.750 0.86 (0.70-1.07) 0.173 0.82 (0.64-1.03) 0.092 
Te reo language (census)
* 
n=5,997 
Te reo vs No te reo 0.71 (0.29-1.72) 0.446 0.72 (0.30-1.75) 0.464 0.31 (0.12-0.81) 0.017 
Time period 2014-2016 vs 2009-2013 1.12 (0.86-1.45) 0.401 1.10 (0.85-1.42) 0.478 1.39 (1.07-1.81) 0.012 





42 vs 41 2.01 (1.19-3.39) <0.001 2.03 (1.20-3.42) <0.001 2.03 (1.20-3.42) <0.001 










































25-29 vs <25  1.24 (0.54-2.83) <0.001 1.18 (0.52-2.71) <0.001 1.18 (0.51-2.75) 0.033 















 Antidepressant use  Yes vs No (5y prior to baseline) 1.16 (0.87-1.56) 0.304 1.22 (0.91-1.63) 0.187 1.24 (0.92-1.68) 0.164 
AMI AMI vs None 1.64 (0.88-3.08) 0.122 1.73 (0.92-3.26) 0.091 1.40 (0.74-2.66) 0.298 
Cancer Cancer vs None 0.71 (0.32-1.59) 0.406 0.84 (0.38-1.89) 0.681 0.82 (0.36-1.84) 0.626 
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 adjusted models 
  Rate ratio p Rate ratio p Rate ratio p 
CHD CHD vs None 1.24 (0.74-2.07) 0.420 1.35 (0.80-2.28) 0.255 1.14 (0.67-1.93) 0.626 
COPD COPD vs None 0.78 (0.40-1.51) 0.462 0.95 (0.49-1.86) 0.891 0.77 (0.40-1.50) 0.444 
Gout Gout vs None 1.48 (1.00-2.21) 0.052 1.39 (0.93-2.08) 0.106 1.20 (0.80-1.80) 0.390 
Stroke Stroke vs None 0.57 (0.14-2.27) 0.422 0.66 (0.17-2.67) 0.564 0.48 (0.12-1.94) 0.304 




Ex-Smoker vs Never Smoker 1.50 (1.06-2.12) <0.001 1.55 (1.09-2.21) 0.002 1.42 (0.98-2.07) 0.067 










Yes vs No 





 Yes vs No 1.59 (1.12-2.25) 0.010 1.46 (1.02-2.08) 0.038 1.08 (0.74-1.57) 0.684 
Mobility in the last five 
years 
2 vs 1 meshblocks 1.07 (0.84-1.36) 0.186 0.99 (0.78-1.26) 0.608 1.01 (0.79-1.29) 0.535 










 Time since most recent 
primary care visit at baseline
 
n=8,067 
6–12 vs < 6 months 1.15 (0.82-1.61) 0.586 0.95 (0.68-1.34) 0.380 0.93 (0.66-1.31) 0.272 

















Lowest vs Highest  1.32 (0.77-2.27) 0.262 1.38 (0.80-2.38) 0.161 0.89 (0.51-1.56) 0.288 
Second vs Highest  1.14 (0.65-2.02)  1.13 (0.64-2.00)  0.87 (0.49-1.55)  
Middle vs Highest  0.82 (0.44-1.52)  0.80 (0.43-1.48)  0.56 (0.30-1.04)  
Fourth vs Highest  0.89 (0.48-1.64)  0.90 (0.49-1.67)  0.77 (0.42-1.43)  
Personal Income quintile 




Lowest vs Highest  1.13 (0.82-1.56) 0.076 1.45 (1.05-2.01) 0.108 1.33 (0.96-1.84) 0.212 
Second vs Highest  0.88 (0.63-1.22)  1.28 (0.91-1.80)  1.10 (0.78-1.54)  
Middle vs Highest  1.00 (0.72-1.37)  1.35 (0.97-1.88)  1.11 (0.80-1.54)  
Fourth vs Highest  1.34 (1.00-1.80)  1.46 (1.08-1.96)  1.37 (1.02-1.84)  





Unemployed vs Full-time 1.45 (0.82-2.54) 0.454 1.56 (0.88-2.73) 0.022 1.19 (0.67-2.13) 0.179 
Not in Workforce vs Full-time 1.01 (0.75-1.37)  1.64 (1.16-2.33)  1.43 (1.01-2.02)  





 Education (census) 
† 
School qualification vs None  1.02 (0.81-1.29) 0.283 0.90 (0.71-1.14) 0.029 1.09 (0.86-1.39) 0.246 
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 adjusted models 
  Rate ratio p Rate ratio p Rate ratio p 





 Each column for each variable of interest represents a separate model. All models are run on the non-missing dataset, maximum =9222.  
*There were additional missing data for these variables however the study population was consistent across the row. Furthermore all analyses on census 
variables; te reo, smoking, urban, crowding, home ownership, household income, workforce status variables were limited to people who got pre-diabetes after the 
March 2013 census to avoid reverse causality. 
‡ SEP variables used were personal income in the previous five years (tax records), 2013 deprivation index at baseline residence, and highest qualification, 
†The models for these socioeconomic position (SEP) variables of interest in the SEP adjusted models were not adjusted for SEP (instead only ethnicity was 
added to the model).  
§HbA1c was adjusted using HbA1c as a continuous variable, and as HbA1c squared. 
||The models for ethnicity variables of interest in the ethnicity adjusted models were not adjusted for ethnicity (instead only SEP was added to the model). 
¶The models for HbA1c variable of interest in the HbA1c adjusted model were adjusted for age, sex, ethnicity, and SEP only. 
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